Jonathan W. Byrnes

Jonathan W. Byrnes

Auto-generated profile, based on publicly available information

Jonathan W. Byrnes

Division of Pediatric Cardiology, Cardiac Critical Care, Children's of Alabama, Birmingham, Alabama

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in ASAIO Journal
Verified
Journal Article
Closed access
JBJonathan Byrnes
Jonathan Byrnes
WMWes McKamie
Wes McKamie
CSChristopher Swearingen
Christopher Swearingen
PPParthak Prodhan
Parthak Prodhan
ABAdnan Bhutta
Adnan Bhutta
RFRichard Fiser
Richard Fiser
Extracorporeal membrane oxygenation (ECMO) is a lifesaving therapy, which has been used for the support of children with a broad range of diseases. Two pumps of differing mechanisms have been used to generate the extracorporeal flow: roller-head pumps and centrifugal pumps. Seven patients supported during ECMO with Levitronix Centrimag (Centrimag group [CG]) were matched to 14 patients supported with Stockert-Shiley SIII (Stockert-Shiley group [SSG]) at a single institution from July 2007 to July 2009. We hypothesized that hemolysis as measured by plasma-free hemoglobin (PFH) is elevated in the SSG versus the CG during cardiac ECMO. Categorical data were analyzed using Fisher's exact test. Plasma-free hemoglobin differences between groups were analyzed using both Wilcoxon rank sum and beta regression. Overall, SSG patients had two times the odds of having a higher PFH than CG patients adjusting for repeated measures (odds ratio [OR] = 1.96, 95% confidence interval [CI]: [1.15–3.34], p < 0.014). Differences between circuit failure in the first 168 hours did not reach statistical significance (1/7 CG vs. 7/14 SSG; p = 0.174). In this population of cardiac patients requiring ECMO support, more hemolysis occurred in the SSG, a roller-head pump supported group, when compared with the CG, a centrifugal pump supported group. Differences in circuit life did not reach statistical significance. This pilot study contrasts with past studies, which have demonstrated more hemolysis occurring with centrifugal pumps when compared with roller-head pumps.

1 May 2014 in Pediatric Critical Care Medicine
Verified
Journal Article
Closed access
KIKatherine Irby
Katherine Irby
CSChristopher Swearingen
Christopher Swearingen
JBJonathan Byrnes
Jonathan Byrnes
JBJoshua Bryant
Joshua Bryant
PPParthak Prodhan
Parthak Prodhan
RFRichard Fiser
Richard Fiser
Objective: Investigate whether anti-Factor Xa levels are associated with the need for change of circuit/membrane oxygenator secondary to thrombus formation in pediatric patients. Design and Settings: Retrospective single institution study. Patients: Retrospective record review of 62 pediatric patients supported with extracorporeal membrane oxygenation from 2009 to 2011. Interventions: Data on standard demographic characteristics, indications for extracorporeal membrane oxygenation, duration of extracorporeal membrane oxygenation, activated clotting time measurements, anti-Factor Xa measurements, and heparin infusion rate were collected. Generalized linear models were used to associate anti-Factor Xa concentrations and need for change of either entire circuit/membrane oxygenator secondary to thrombus formation. Measurements and Main Results: Sixty-two patients met study inclusion criteria. No-circuit change was required in 45 of 62 patients. Of 62 patients, 17 required change of circuit/membrane oxygenator due to thrombus formation. Multivariate analysis of daily anti-Factor Xa measurements throughout duration of extracorporeal membrane oxygenation support estimated a mean anti-Factor Xa concentration of 0.20 IU/mL (95% CI, 0.16, 0.24) in no-complete-circuit group that was significantly higher than the estimated concentration of 0.13 IU/mL (95% CI, 0.12, 0.14) in complete-circuit group (p = 0.001). A 0.01 IU/mL decrease in anti-Factor Xa increased odds of need for circuit/membrane oxygenator change by 5% (odds ratio = 1.105; 95% CI, 1.00, 1.10; p = 0.044). Based on the observed anti-Factor Xa concentrations, complete-circuit group had 41% increased odds for requiring circuit/membrane oxygenator change compared with no-complete-circuit group (odds ratio = 1.41; 95% CI, 1.01, 1.96; p = 0.044). Mean daily activated clotting time measurement (p = 0.192) was not different between groups, but mean daily heparin infusion rate (p < 0.001) was significantly different between the two groups. Conclusions: Higher anti-Factor Xa concentrations were associated with freedom from circuit/membrane oxygenator change due to thrombus formation in pediatric patients during extracorporeal membrane oxygenation support. Activated clotting time measurements did not differ significantly between groups with or without circuit/membrane oxygenator change. This is the first study to link anti-Factor Xa concentrations with a clinically relevant measure of thrombosis in pediatric patients during extracorporeal membrane oxygenation support. Further prospective study is warranted.

1 January 2014 in ASAIO Journal
Verified
Journal Article
Closed access
JBJonathan W. Byrnes
Jonathan W. Byrnes
CSChristopher J. Swearingen
Christopher J. Swearingen
PPParthak Prodhan
Parthak Prodhan
RFRichard Fiser
Richard Fiser
UDUmesh Dyamenahalli
Umesh Dyamenahalli
Antithrombin III (ATIII) is used during extracorporeal membrane oxygenation (ECMO) based on physiologic rationale and studies during cardiopulmonary bypass. In February 2008, our institution began using ATIII as replacement for low ATIII activity (72 hours with venoarterial ECMO from January 1, 2007, through December 31, 2008, were collected. Antithrombin III concentrate was administered for ATIII activity <70% at the discretion of the attending physician. The primary outcome was whether the heparin infusion rate was reduced by 10% or more as a result of ATIII administration. No difference in heparin infusion rate (p = 0.245) as a result of ATIII administration was observed. Anti-Xa levels were lower before ATIII administration (p< 0.001) and were increased after ATIII administration (p < 0.001). There was an increased frequency of circuit failure in ATIII treatment group compared with nontreatment group (p = 0.018). Neither heparin responsiveness nor circuit life was enhanced by daily ATIII supplementation for activity <70%. Future studies are warranted to evaluate the effectiveness of antithrombin replacement.

1 November 2013 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
JBJonathan W. Byrnes
Jonathan W. Byrnes
PPParthak Prodhan
Parthak Prodhan
BWBlake A. Williams
Blake A. Williams
MSMichael L. Schmitz
Michael L. Schmitz
MMM. Michele Moss
M. Michele Moss
ABAdnan T. Bhutta
Adnan T. Bhutta

1 April 2015 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
JBJonathan W. Byrnes
Jonathan W. Byrnes
ABAdnan T. Bhutta
Adnan T. Bhutta
MRMallikarjuna Rao Rettiganti
Mallikarjuna Rao Rettiganti
AGAlberto Gomez
Alberto Gomez
XGXiomara Garcia
Xiomara Garcia
PPParthak Prodhan
Parthak Prodhan

8 March 2016 in World Journal for Pediatric and Congenital Heart Surgery
Verified
Journal Article
Closed access
DHDavid A. Hehir
David A. Hehir
RER. Blaine Easley
R. Blaine Easley
JBJonathan Byrnes
Jonathan Byrnes
Outcomes following cardiac intensive care unit (CICU) admission are influenced by many factors including initial cardiac diagnosis, surgical complexity, and burden of critical illness. Additionally, the presence of noncardiac issues may have a significant impact on outcomes and the patient experience during and following an intensive care unit stay. This review focuses on three common noncardiac areas which impact outcomes and patient experience in and beyond the CICU: feeding and growth, pain and analgesia, and anticoagulation. Growth failure and feeding dysfunction are commonly encountered in infants requiring cardiac surgery and have been associated with worse surgical and developmental outcomes. Recent studies most notably in the single ventricle population have demonstrated improved weight gain and outcomes when feeding protocols are implemented. Children undergoing cardiac surgery may experience both acute and chronic pain. Emerging research is investigating the impact of sedatives and analgesics on neurodevelopmental outcomes and quality of life. Improved pain scores and standardized management of pain and withdrawal may improve the patient experience and outcomes. Effective anticoagulation is a critical component of perioperative care but may be complicated by inflammation, multiorgan dysfunction, and patient factors. Advances in monitoring of anticoagulation and emerging therapies are reviewed.